Utah’s business landscape is rich with professionals who have le...Read More
Social Media and Employers: Friends or Enemies?
The Case for HSAs
Time to Show Up
Make a Move
In the Lab
Rent to Own
Back from the Dead
A Breath of Fresh Air
Travel & Tourism
SALT LAKE CITY — ThermImage, Inc., a Salt Lake City-based developer of medical devices, has been chosen to receive a Phase I Small Business Innovation Research Grant from the National Institutes of Health. Fewer than 20 percent of all applications are approved and funded by the agency, which is part of the Department of Health and Human Services.
“The news that we have been selected to receive funding to further develop our unique technology is tremendously exciting,” said Doug Turnquist, president and chief executive officer of ThermImage. “But more important is the affirmation of this technology by the National Institutes of Health of our belief that we not only have a unique and exciting technology but also that we have a technology that will improve patient care while decreasing overall costs of care by reducing costly complications.”
The award was made to support ongoing development activities for the AccuCor DTMS, a noninvasive brain temperature monitoring system that is currently in the final stage of development before being submitted for regulatory approvals to make the system available for use in hospitals worldwide. The system is expected to be the first commercially available noninvasive method of directly measuring the temperature deep within the brain, which often differs significantly from temperatures measured anywhere else in the body. The ability of the system to provide brain temperature information to physicians promises to reduce neurological complications in cardiac surgery and to improve outcomes in patients being treated in neurological intensive care units.
ThermImage expects to receive CE Marking within the next year, which will allow the system to be marketed in Europe. The company will also seek clearance for the AccuCor DTMS from the U.S. Food and Drug Administration to support a U.S. market launch in 2014.